{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "The recent decision by Abbott Laboratories to quintuple the price of its crucial AIDS drug Norvir will be at the center of a federal hearing today in which AIDS groups and consumer advocates plan to argue that the government should begin allowing the import of cheaper drugs. The hearing, which will be conducted by the Department of Health and Human Services, is a result of last fall's Medicare drug legislation, in which Congress called for a general inquiry into the import question. But the escalating protest over Norvir, whose average annual dosage cost rose to about $7,800 in January from $1,500, has suddenly given the import issue unexpected urgency.", "headline": {"main": "Price of AIDS Drug Intensifies Debate On Legal Imports"}, "abstract": "Recent decision by Abbott Laboratories to quintuple price of its crucial AIDS drug Norvir will be at center of Federal Health and Human Servicers hearing in which AIDS groups and consumer advocates plan to argue that government should begin allowing import of cheaper drugs; hearing is result of last fall's Medicare drug legislation, in which Congress called for general inquiry into import question; but escalating protest over Norvir, whose average annual dosage cost rose to about $7,800 in January from $1,500, has suddenly given import issue unexpected urgency; table shows how costs for various prescription drugs in US exceed those in other industrial countries; photo (M)", "print_page": "1", "word_count": 1433, "_id": "4fd27d558eb7c8105d844e42", "snippet": "The recent decision by Abbott Laboratories to quintuple the price of its crucial AIDS drug Norvir will be at the center of a federal hearing today in which AIDS groups and consumer advocates plan to argue that the government should begin allowing the...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/04/14/business/price-of-aids-drug-intensifies-debate-on-legal-imports.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "ABBOTT LABORATORIES INC"}, {"name": "subject", "value": "ACQUIRED IMMUNE DEFICIENCY SYNDROME"}, {"name": "subject", "value": "INTERNATIONAL TRADE AND WORLD MARKET"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "NORVIR (DRUG)"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Gardiner", "lastname": "HARRIS"}], "original": "By GARDINER HARRIS"}, "document_type": "article", "pub_date": "2004-04-14T00:00:00Z", "section_name": "Front Page; Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Sports Desk", "lead_paragraph": "BARRY BONDS, who hit his 661st home run last night and now trails only Hank Aaron and Babe Ruth, has denied using steroids, but he hasn't convinced everybody. An unprecedented torrent of 213 home runs in four seasons covering his late 30's can have that effect. After Bonds hit the 660th of his career Monday, tying Willie Mays, ESPN provided periodic live reports from its anchor and three baseball analysts, but none of them mentioned steroids and at least the possibility that steroids have contributed to his late-career outburst, or whether his accomplishments would be tainted by the suspicion of steroids use.", "headline": {"main": "On Baseball; Owners Have Not Acted To Stop Use of Steroids"}, "abstract": "Murray Chass On Baseball column accuses Major League Baseball club owners of inaction on issue of steroid use, contending that as group they have missed opportunities to solve problems (M)", "print_page": "5", "word_count": 903, "_id": "4fd2535b8eb7c8105d7f9cfb", "snippet": "BARRY BONDS, who hit his 661st home run last night and now trails only Hank Aaron and Babe Ruth, has denied using steroids, but he hasn't convinced everybody. An unprecedented torrent of 213 home runs in four seasons covering his late 30's can have...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/04/14/sports/on-baseball-owners-have-not-acted-to-stop-use-of-steroids.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "BASEBALL"}, {"name": "subject", "value": "STEROIDS"}, {"name": "subject", "value": "DRUG ABUSE AND TRAFFIC"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Murray", "lastname": "CHASS"}], "original": "By MURRAY CHASS"}, "document_type": "article", "pub_date": "2004-04-14T00:00:00Z", "section_name": "Sports"}, {"type_of_material": "News", "blog": [], "news_desk": "Retirement", "lead_paragraph": "WITH new government-endorsed drug discount cards becoming available June 1, many Medicare recipients are facing a difficult task in comparison shopping. Twenty-eight companies have been approved by the federal government to market the cards, which should lower prescription drug costs by 10 to 25 percent. The discount cards are a stopgap, part of the broad Medicare bill enacted in December that, among other measures, provides a comprehensive, federally subsidized Medicare drug benefit starting in 2006.", "headline": {"main": "Discount Drug Cards Are Coming: It's Time to Do Your Homework", "kicker": "MEDICARE"}, "abstract": "Many Medicare recipients are facing difficult task in comparison shopping for new government-endorsed drug discount cards that will be available June 1; government has approved 28 companies to market cards, which should cut prescription drug costs by 10 to 25 percent; cards are stopgap until comprehensive subsidized Medicare drug benefit starts in 2006; drawing (M)", "print_page": "4", "word_count": 1040, "_id": "4fd2390d8eb7c8105d7cc8b0", "snippet": "WITH new government-endorsed drug discount cards becoming available June 1, many Medicare recipients are facing a difficult task in comparison shopping.    Twenty-eight companies have been approved by the federal government to market the cards, which...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/04/13/jobs/medicare-discount-drug-cards-are-coming-it-s-time-to-do-your-homework.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "HEALTH INSURANCE AND MANAGED CARE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1}], "original": "By ROBERT D. HERSHEY Jr"}, "document_type": "article", "pub_date": "2004-04-13T00:00:00Z", "section_name": "Health; Job Market"}, {"type_of_material": "News", "blog": [], "news_desk": "Retirement", "lead_paragraph": "SILOY ABDOOL of the Bronx started putting money aside for retirement when she was in her mid-30's. Two years ago, she left her teaching job after she had a baby and could not find good, affordable child care. Now she is 43, separated from her husband and her nest egg has been used up. ''If I go back, I'm going to have to double up,'' Ms. Abdool said, referring to the pace of her savings. ''I don't know how I'm going to do it.''", "headline": {"main": "On Their Own, in the Same Boat", "kicker": "LOOKING AHEAD"}, "abstract": "Single women of baby boom gen", "print_page": "1", "word_count": 1981, "_id": "4fd27d528eb7c8105d844b52", "snippet": "SILOY ABDOOL of the Bronx started putting money aside for retirement when she was in her mid-30's. Two years ago, she left her teaching job after she had a baby and could not find good, affordable child care. Now she is 43, separated from her husband...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/04/13/jobs/looking-ahead-on-their-own-in-the-same-boat.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "MILBANK MEMORIAL FUND"}, {"name": "organizations", "value": "EMPLOYEE BENEFIT RESEARCH INSTITUTE"}, {"name": "subject", "value": "MEN"}, {"name": "subject", "value": "WOMEN"}, {"name": "subject", "value": "PENSIONS AND RETIREMENT PLANS"}, {"name": "subject", "value": "RESEARCH"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Mary", "lastname": "DUENWALD"}, {"organization": "", "role": "reported", "rank": 2, "firstname": "Bernard", "lastname": "STAMLER"}], "original": "By MARY DUENWALD and BERNARD STAMLER"}, "document_type": "article", "pub_date": "2004-04-13T00:00:00Z", "section_name": "Job Market"}, {"type_of_material": "News", "blog": [], "news_desk": "Magazine Desk", "lead_paragraph": "The year 2000 was a time of plague for the South African town of Ndumo, on the border of Mozambique. That March, while the world was focused on AIDS, more than 7,000 people came to the local health clinic with malaria. The South African Defense Force was called in, and soldiers set up tents outside the clinic to treat the sick. At the district hospital 30 miles away in Mosvold, the wards filled with patients suffering with the headache, weakness and fever of malaria -- 2,303 patients that month. ''I thought we were going to get buried in malaria,'' said Hervey Vaughan Williams, the hospital's medical manager. Today, malaria has all but vanished in Ndumo. In March 2003, the clinic treated nine malaria cases; Mosvold Hospital, only three.", "headline": {"main": "What the World Needs Now Is DDT"}, "abstract": "Tina Rosenberg article calls for careful use of in developing countries of DDT, insecticide banned because of its persistence in environment, to fight mosquitoes that spread malaria; cites South Africa's renewed use of DDT, most effective and cheapest alternative, to bring malaria back under control; notes malaria kills some two million people a year, mainly children under 5 and 90 percent of them in Africa; notes spraying in tiny quantities inside houses is most likely not harmful to people or environment; photos (L)", "print_page": "38", "word_count": 5032, "_id": "4fd27b348eb7c8105d8401e0", "snippet": "The year 2000 was a time of plague for the South African town of Ndumo, on the border of Mozambique. That March, while the world was focused on AIDS, more than 7,000 people came to the local health clinic with malaria. The South African Defense Force...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/04/11/magazine/what-the-world-needs-now-is-ddt.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "AFRICA"}, {"name": "glocations", "value": "SOUTH AFRICA"}, {"name": "subject", "value": "PESTICIDES"}, {"name": "subject", "value": "CHILDREN AND YOUTH"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "MALARIA"}, {"name": "subject", "value": "MOSQUITOES"}, {"name": "subject", "value": "THIRD WORLD AND DEVELOPING COUNTRIES"}, {"name": "subject", "value": "DDT (DICHLORODIPHENYLTRICHLOROETHANE)"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Tina", "lastname": "Rosenberg"}], "original": "By Tina Rosenberg"}, "document_type": "article", "pub_date": "2004-04-11T00:00:00Z", "section_name": "Magazine"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Diane Adkins, who has a life-threatening lung disease, used to take a drug that cost more than $100,000 a year and that had to be pumped round the clock into a vein through a hole in her chest. Now she has replaced it with a pill that costs about $10,000 a year. But her insurance company will not pay for the cheaper drug, even though it paid for the more expensive one. As the company explained in a letter, ''Your benefit program covers this medication for men over the age of eighteen (18) only.''", "headline": {"main": "Viagra Gains Some Advocates As Treatment For Lung Disease"}, "abstract": "Viagra, Pfizer drug for erectile dysfunction, is being tested for treatment of pulmonary hypertension, rare but deadly disease, affecting mainly women, in which extremely high pressure in artery that carries blood from heart to lungs can make even routine tasks an ordeal; clinical trial in India, involving only 12 patients, found that Viagra increased ability of patients to exercise by 40 percent; Pfizer expects results of its own much larger and more definitive trial around middle of year; some doctors and insurance companies say they are concerned about use of Viagra to treat pulmonary hypertension, contending it has not been proved effective in rigorous clinical trials; graph shows total prescriptions for Viagra and two other drugs for erectile dysfunction, Levitra anbd Cialis; photos (L)", "print_page": "1", "word_count": 1688, "_id": "4fd2391a8eb7c8105d7cce3e", "snippet": "Diane Adkins, who has a life-threatening lung disease, used to take a drug that cost more than $100,000 a year and that had to be pumped round the clock into a vein through a hole in her chest. Now she has replaced it with a pill that costs about...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/04/10/business/viagra-gains-some-advocates-as-treatment-for-lung-disease.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "PFIZER INC"}, {"name": "subject", "value": "SEX"}, {"name": "subject", "value": "HEALTH INSURANCE AND MANAGED CARE"}, {"name": "subject", "value": "CIALIS (DRUG)"}, {"name": "subject", "value": "IMPOTENCE"}, {"name": "subject", "value": "PULMONARY HYPERTENSION"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "VIAGRA (DRUG)"}, {"name": "subject", "value": "WOMEN"}, {"name": "subject", "value": "LUNGS"}, {"name": "subject", "value": "LEVITRA (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2004-04-10T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Pediatricians and family physicians should not prescribe antidepressants for depressed children and adolescents because the drugs barely work and their side effects are often significant, Australian researchers have concluded. The researchers analyzed data from five published trials of three antidepressants, Prozac, Zoloft and Paxil, in depressed patients under age 18. They found that the drugs offered only a ''very modest'' benefit over placebos.", "headline": {"main": "Study Advises Against Drugs For Children In Depression"}, "abstract": "Australian researchers conclude that pediatricians and family physicians should not prescribe antidepressants for depressed children and adolescents because drugs barely work and their side effects are often significant; study is published in British medical journal BMJ; it is latest salvo in increasingly bitter war over whether prescribing antidepressants to children and adolescents is appropriate (M)", "print_page": "16", "word_count": 522, "_id": "4fd29f698eb7c8105d88320d", "snippet": "Pediatricians and family physicians should not prescribe antidepressants for depressed children and adolescents because the drugs barely work and their side effects are often significant, Australian researchers have concluded.    The researchers...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/04/09/us/study-advises-against-drugs-for-children-in-depression.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "AUSTRALIA"}, {"name": "organizations", "value": "BMJ"}, {"name": "subject", "value": "CHILDREN AND YOUTH"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "ANTIDEPRESSANTS"}, {"name": "subject", "value": "DEPRESSION (MENTAL)"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Gardiner", "lastname": "HARRIS"}], "original": "By GARDINER HARRIS"}, "document_type": "article", "pub_date": "2004-04-09T00:00:00Z", "section_name": "Health; U.S."}], "meta": {"hits": 7, "offset": 0, "time": 194}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}